Informations générales (source: ClinicalTrials.gov)
Role of Clonal Hematopoiesis and NETs Formation in Unusual Venous Thrombosis (CLODETTE) (CLODETTE)
Interventional
N/A
University Hospital, Bordeaux (Voir sur ClinicalTrials)
mars 2023
mars 2027
05 avril 2025
Thrombo-embolic venous diseases are represented by deep venous thrombosis and/or
pulmonary embolism. In some patients with repeated thrombosis or occurrence of thrombosis
in unusual sites, the etiological workup remains negative, which represents a problem for
the management of the anticoagulant treatments. Recently, two factors have been
identified as important in the physiopathology of hemostasis and coagulation: the
presence of clonal hematopoiesis of indetermined potential (CHIP) and the formation of
neutrophil extracellular traps (NETs). In this study, these two factors will be studied
in patients with repeated venous thrombosis or thrombosis occurring in unusual site.
Etablissements
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| APHM - Hôpital de la Timone, Service Hématologie - Marseille - France | Pierre SUCHON | Contact (sur clinicalTrials) | |||
| CHU de Bordeaux, Service de Neurologie - Bordeaux - France | Igor SIBON | Contact (sur clinicalTrials) | |||
| CHU de Bordeaux, Service Gastro-Entérologie - Bordeaux - France | Paul HERMABESSIERE | Contact (sur clinicalTrials) | |||
| CHU de Bordeaux, Service Hématologie Biologique - Bordeaux - France | Alexandre GUY | Contact (sur clinicalTrials) | |||
| CHU de Bordeaux, Service Médecine Vasculaire - Bordeaux - France | Joël CONSTANS | Contact (sur clinicalTrials) | |||
| CHU de Bordeaux, Unité ambulatoire de Médecine Vasculaire - Bordeaux - France | Sophie SKOPINSKI | Contact (sur clinicalTrials) | |||
| CHU de Lille, Service Hémostase Clinique - Lille - France | Nathalie TRILLOT | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patients (male or female) less than 50 y.o with :
- Splanchnic venous territory thrombosis or
- Cerebral venous thrombosis or
- Venous thrombosis of the upper limb or
- Pulmonary embolism (1st episode if male, 2nd episode if female) unprovoked or
- 1 episode of deep vein thrombosis + 1 episode of arterial thrombosis
- Patients (male or female) less than 50 y.o with :
- Splanchnic venous territory thrombosis or
- Cerebral venous thrombosis or
- Venous thrombosis of the upper limb or
- Pulmonary embolism (1st episode if male, 2nd episode if female) unprovoked or
- 1 episode of deep vein thrombosis + 1 episode of arterial thrombosis
- Presence of a major or minor transient venous thrombosis risk factor:
- Surgery within the last 3 months preceding the qualifying thrombotic episode
- Lower limb fracture with immobilization > 3 days in the last 3 months preceding the
qualifying thrombotic episode
- Presence of estro-progestational contraception
- Pregnancy
- Immobilization for acute medical reasons within the last 3 months preceding the
qualifying thrombotic episode
- Air or car travel > 6 hours
- Presence of a major or minor persistent risk factor for venous thrombosis:
- Presence of active cancer (solid cancer or hematologic malignancy)
- Chronic inflammatory digestive or joint diseases
- Ongoing treatment with heparin (low molecular weight heparin (LMWH) or
unfractionated heparin (UFH))
- Presence of an abnormality on the thrombophilia test among the following
abnormalities
- Protein C deficiency
- Protein S deficiency
- Anti-thrombin deficiency
- Heterozygous or homozygous factor II mutation
- Heterozygous or homozygous factor V mutation
- Presence of anti-phospholipid syndrome
- Presence of myeloproliferative neoplasia
- Presence of paroxysmal nocturnal hemoglobinuria